


## AMENDMENTS TO THE CLAIMS

1. (Original) A compound represented by the formula (I):




wherein R<sup>2</sup> and R<sup>3</sup> are the same or different and each is C2-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxyC1-C4 alkyl, optionally substituted aminoC1-C4 alkyl, or C3-C6 cycloalkylC1-C4 alkyl; or

R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form an optionally substituted 5 to 8 membered non-aromatic carbocyclic ring or an optionally substituted 5 to 8 membered non-aromatic heterocyclic ring;

R<sup>4</sup> is C1-C6 alkyl, hydroxyC1-C6alkyl, optionally substituted aminoC1-C6alkyl, or C1-C6 alkoxyC1-C6 alkyl;

X is an oxygen atom or a sulfur atom;

A is the group of the formula:



wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, alkylthio, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, optionally substituted aralkyloxy, cycloalkyl, a halogen atom, hydroxy, nitro, haloalkyl, haloalkoxy, optionally substituted carbamoyl, carboxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, alkoxyalkyl, alkylthioalkyl, optionally substituted aminoalkyl, alkoxyiminoalkyl, alkoxyalkoxy, alkylthioalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy, alkylsulfonyloxy, optionally substituted heteroaryl, an optionally substituted non-aromatic heterocyclic group, cyano, cyanoalkoxy, or a group of the formula: -C(=O)-R<sup>H</sup> wherein R<sup>H</sup> is a hydrogen atom, alkyl, optionally substituted aryl, or an optionally substituted non-aromatic heterocyclic group;

W is C2-C6 alkylene which may contain an optionally substituted heteroatom(s) or C2-C4 alkenylene which may contain an optionally substituted heteroatom(s);


n is an integer of 0 to 7;

a pharmaceutically acceptable salt, or a solvate thereof.

**2. (Original)** The compound according to Claim 1 wherein R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form an optionally substituted 5 to 6 membered carbocyclic ring, a pharmaceutically acceptable salt, or a solvate thereof.

**3. (Original)** The compound according to Claim 1 or 2 wherein W is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -N(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , or -CH=CH-CH=CH-, a pharmaceutically acceptable salt, or a solvate thereof.

**4. (Original)** A compound of the formula (II):



wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, optionally substituted amino, a halogen atom, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxy carbonylalkoxy;

each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C4 alkyl; or

R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form 5 to 6 membered cycloalkane;

R<sup>4</sup> is C1-C6 alkyl;

X is an oxygen atom or a sulfur atom;


n is an integer of 0 to 7;

a pharmaceutically acceptable salt, or a solvate thereof.

**5. (Original)** The compound according to Claim 4 wherein R<sup>1</sup> is a fluorine atom, a chlorine atom, dimethylamino, cyano, or t-butoxycarbonylmethoxy, a pharmaceutically acceptable salt, or a solvate thereof.

**6. (Original)** The compound according to Claim 4 or 5 wherein n is 0 or 1, a pharmaceutically acceptable salt, or a solvate thereof.

**7. (Original)** A compound of the formula (II):



wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, optionally substituted amino, a halogen atom, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxy carbonylalkoxy;

each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C4 alkyl; or

R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form 5 to 6 membered cycloalkane;

R<sup>4</sup> is C1-C6 alkyl;

X is an oxygen atom or a sulfur atom;

Z is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , or -OCH<sub>2</sub>CH<sub>2</sub>O-;

n is an integer of 0 to 3;

a pharmaceutically acceptable salt, or a solvate thereof.

**8. (Original)** The compound according to Claim 7 wherein Z is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , a pharmaceutically acceptable salt, or a solvate thereof.

**9. (Original)** The compound according to Claim 7 wherein Z is -OCH<sub>2</sub>CH<sub>2</sub>O- , a pharmaceutically acceptable salt, or a solvate thereof.

**10. (Currently Amended)** The compound according to ~~any one of~~ Claim 7 wherein n is 0, a pharmaceutically acceptable salt, or a solvate thereof.

**11. (Original)** The compound according to any one of Claim 4 or 7 wherein R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form 6 membered cycloalkane, a pharmaceutically acceptable salt, or a solvate thereof.

**12. (Currently Amended)** The compound according to any one of Claims 1, 4 and 7 and 3 to 10 wherein each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C3 alkyl, a pharmaceutically acceptable salt, or a solvate thereof.

**13. (Currently Amended)** The compound according to any one of Claims 1, 4 and 7 to 11 wherein R<sup>4</sup> is methyl or ethyl, a pharmaceutically acceptable salt, or a solvate thereof.

**14. (Currently Amended)** A pharmaceutical composition which contains the compound according to any one of Claims 1, 4 and 7 to 13, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.

**15. (Currently Amended)** A pharmaceutical composition which contains the compound according to any one of Claims 1, 4 and 7 to 13, which has a cannabinoid receptor agonistic activity, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.,

**16. (Currently Amended)** The pharmaceutical composition according to any one of Claim 14 or 15 which is useful for an analgesics.

**17. (Currently Amended)** The pharmaceutical composition according to any one of Claim 14 or 15 which is useful for a treating agent for algesic.

**18. (Currently Amended)** The pharmaceutical composition according to any one of Claim 14 or 15 which is useful for an antipruritics.

**19. (Currently Amended)** The pharmaceutical composition according to any one of Claim 14 or 15 which is useful for a bronchodilator[[],].

**20. (Currently Amended)** A method for treating a disease related to a cannabinoid receptor which comprises administering the compound according to any one of Claims 1, 4 and 7 to 13, a pharmaceutically acceptable salt, or a solvate thereof.

**21. (Currently Amended)** ~~A method Use of the compound according to any one of Claims 1 to 13~~ for manufacturing a treating agent for a disease related to a cannabinoid receptor, a pharmaceutically acceptable salt, or a solvate thereof which comprises employing in said agent a compound according to any one of claims 1, 4 and 7.

**22. (New)** The pharmaceutical composition according to Claim 15 which is useful for an analgesics.

**23. (New)** The pharmaceutical composition according to Claim 15 which is useful for a treating agent for algesic.

**24. (New)** The pharmaceutical composition according Claim 15 which is useful for an antipruritics.

**25. (New)** The pharmaceutical composition according to Claim 15 which is useful for a bronchodilator.